160 related articles for article (PubMed ID: 33437697)
21. Expression and Clinical Significance of ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients.
Sadeghipour A; Taha SR; Shariat Zadeh M; Kosari F; Babaheidarian P; Fattahi F; Abdi N; Tajik F
Appl Immunohistochem Mol Morphol; 2024 Jun; ():. PubMed ID: 38872345
[TBL] [Abstract][Full Text] [Related]
22. The Hans algorithm failed to predict outcome in patients with diffuse large B-cell lymphoma treated with rituximab.
Benesova K; Forsterova K; Votavova H; Campr V; Stritesky J; Velenska Z; Prochazka B; Pytlik R; Trneny M
Neoplasma; 2013; 60(1):68-73. PubMed ID: 23067219
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified.
Cho I; Yoon N; Hyeon J; Sim J; Yoo HY; Kim SJ; Kim WS; Ko YH
Appl Immunohistochem Mol Morphol; 2020; 28(10):731-740. PubMed ID: 32287077
[TBL] [Abstract][Full Text] [Related]
24. Diffuse large B cell lymphoma CD5-positive arising in an immune deficiency and immune dysregulation setting: A case report and brief review of the literature.
Cristian M; Baz RA; Stoica AG; Așchie M; Ghinea MM; Deacu M; Boșoteanu M; Mitroi AF; Dobrin N; Iordache IE; Bălțătescu GI
Medicine (Baltimore); 2023 Feb; 102(8):e33083. PubMed ID: 36827036
[TBL] [Abstract][Full Text] [Related]
25. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
26. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study.
Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ
J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664
[TBL] [Abstract][Full Text] [Related]
27. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
[TBL] [Abstract][Full Text] [Related]
28. Different predictive values of interim
Kim J; Lee JO; Paik JH; Lee WW; Kim SE; Song YS
Ann Nucl Med; 2017 Jan; 31(1):1-11. PubMed ID: 27627889
[TBL] [Abstract][Full Text] [Related]
29. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
[TBL] [Abstract][Full Text] [Related]
30. Classifying DLBCL according cell of origin using Hans algorithm and its association with clinicopathological parameters: A single centre experience.
Wn Najmiyah WAW; Azlan H; Faezahtul AH
Med J Malaysia; 2020 Mar; 75(2):98-102. PubMed ID: 32281588
[TBL] [Abstract][Full Text] [Related]
31. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
[TBL] [Abstract][Full Text] [Related]
32. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
[TBL] [Abstract][Full Text] [Related]
33. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Joseph J; Ma J; Hennawy F; Abdulrazzaq MN; Saini N; Patel RD; Hosing CM; Alousi AM; Anderlini P; Popat UR; Qazilbash MH; Shpall EJ; Srour S; Kebriaei P; Bashir Q; Nastoupil LJ; Westin JR; Rondon G; Champlin RE; Andersson BS; Nieto Y; Muzzafar T; Ahmed S
Transplant Cell Ther; 2021 May; 27(5):404.e1-404.e5. PubMed ID: 33965178
[TBL] [Abstract][Full Text] [Related]
34. Role of Cell-Origin Profiling Using Immunohistochemistry to Predict the Survival of Patients with Diffuse Large B-Cell Lymphoma in Indonesia.
Istiadi H; Sadhana U; Puspasari D; Miranti IP; Karlowee V; Listiana DE; Prasetyo A
Yonago Acta Med; 2021 May; 64(2):200-206. PubMed ID: 34025195
[TBL] [Abstract][Full Text] [Related]
35. Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma.
Kreher S; Jöhrens K; Strehlow F; Martus P; Borowiec K; Radke J; Heppner F; Roth P; Thiel E; Pietsch T; Weller M; Korfel A
Neuro Oncol; 2015 Jul; 17(7):1016-21. PubMed ID: 25817328
[TBL] [Abstract][Full Text] [Related]
36. [PROGNOSTIC ROLE OF NF-κB EXPRESSION IN DIFFUSE LARGE B-CELL LYMPHOMA SUBGROUPS].
Škunca Z; Planinc-Peraica A
Acta Med Croatica; 2015 Mar; 69(1):25-32. PubMed ID: 26606782
[TBL] [Abstract][Full Text] [Related]
37. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
38. Application of Hans Algorithm for Subcategorization of Diffuse Large B-Cell Lymphoma in Fine-Needle Aspiration Biopsy Cytology.
Rohilla M; Garg S; Bal A; Das A; Gupta N; Dey P; Srinivasan R
Acta Cytol; 2022; 66(1):14-22. PubMed ID: 34788750
[TBL] [Abstract][Full Text] [Related]
39. Array-comparative genomic hybridization profiling of immunohistochemical subgroups of diffuse large B-cell lymphoma shows distinct genomic alterations.
Guo Y; Takeuchi I; Karnan S; Miyata T; Ohshima K; Seto M
Cancer Sci; 2014 Apr; 105(4):481-9. PubMed ID: 24843885
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.
Haarer CF; Roberts RA; Frutiger YM; Grogan TM; Rimsza LM
Arch Pathol Lab Med; 2006 Dec; 130(12):1819-24. PubMed ID: 17149956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
